In the efficacy population, anemia was detected in 22/34 patients (67.7%) at baseline; in particular, 5 received erythropoiesis stimulating agents (all but one had Hb < 12 g/dL) and 17 had hemoglobin below the sex-specific cut-off without receiving erythropoiesis stimulating agents. The gene discussed is GSTM1; the disease is anemia.